Aetiology of pulmonary dysfunction in total hip replacement operations: The influence of nifedipine on the factors involved by Du Toit, H. J. et al.
SAMJ VOLUME 71 7 MARCH 1987 279
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Summary
Patients undergoing total hip replacement surgery
who developed pulmonary dysfunction (PO) demon-
strated evidence of complement activation and
increased thromboxane A2 (TXA0 synthesis. In a
double-blind study nifedipine (Adalat; Bayer-Miles)
was shown to inhibit complement activation and
TXA2 synthesis and thus appears to offer protection
against PD.
S Atr Med J 1987; 71: 279-282.
It is well established that activation of the complement system
resulting in activation of leucocytes, ·and subsequent pulmonary
capillary endothelial damage and leakage of serum and red
blood cells into the interstitial tissue and alveoli, are integral
components of the adult respiratory distress syndrome
(ARDS).l Uncertainty exists about the aetiology of the vascular
changes present in ARDS, but prostaglandins, notably
thromboxane A2 (TXA2), seem to play an important role. 2
Fein el al. 3 stated that pulmonary dysfunction (PD) is just a
milder form of ARDS, and depending on the trigger mechanism
may progress to ARDS. Both terms will be used as appropriate
or in accordance with the terminology used in our references
in this report.
The aim of this study was to establish the role of the
complement system in the development of PD in patients
undergoing total hip replacement under general anaesthesia
and the interrelationships between complement activation,
TXA2 and prostacyclin (PGI2) levels in this condition. Finally,
in a double-blind study the effect of nifedipine (Adalat; Bayer-
Miles) administration on the incidence of PD was investigated.
Patients and methods
The protocol was approved by the ethics comminee of the Univer-
sity of Stellenbosch Medical School and informed consent was
obtained from all patients involved, who were scheduled for hip
replacement surgery. No prostaglandin antagonists or steroids
were allowed during the week preceding the operation. Patients
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were randomly allocated to the treatment or placebo group in a
double-blind manner. Twenty-one patients (18 women and 3 men,
mean age 74 years, range 66 - 84) years were entered into the
study. The 11 patients in the treatment group received oral
nifedipine 10 mg 8 hourly for 2 days before surgery, on the day of
operation and on the first postoperative day; 10 patients served as
controls. Both groups were given a general anaesthetic with similar
agents and were ventilated with a fractional oxygen concentration
(Fio2) of 0,4.'
Monitors. Arterial pressure was continuously monitored via a
20 G radial artery catheter, an AE 840 pressure transducer and a
Simonsen and Wee! oscilloscope with digital display. Central
venous pressure was monitored with a water manometer. Expiratory
carbon dioxide was monitored using a Godart infant capnograph.
Arterial carbon dioxide tension (Paco2), arterial partial pressure of
oxygen (Pao2) and pH were determined with a Gas Check AVL
apparatus at the same time that other measurements were
performed. ECG, oesophageal temperature and Fio2 were also
monitored continuously. During the trial period all parameters
were within normal ranges.
Frequency of sampling
Blood samples were withdrawn at set measurement times: (I)
just before induction of anaesthesia; (il) 30 minutes after stable
anaesthesia was established; (iil) 5 minutes after femoral prosthesis
placement; (iv) at the end of the operation; and (v) about 24 hours
after the operation.
Sampling
Thromboxane B2 (TXB2 - the stable metabolite of TXAJ, 6-
ketoprostaglandin (PG) F10! - the stable metabolite of PGI2),
activated complement 5 (C5a), f3-thromboglobulin (13-TG), a full
blood count, coagulation profile and blood gases were determined.
Preparation of tubes for TXB2, 6-ketoPGF1a,
and /3-TG specimens
Stock solutions were prepared as follows; 10 g/dl ethylene-
diaminetetra-acetic acid (EDTA) and 540 g/dl theophylline were
dissolved in distilled water and the pH adjusted to 7,0. Aspirin
120 mg was added to I ml of methyl alcohol.
On the day of sampling 40 ill of aspirin solution was added to
200 }.LI theophylline-EDTA solution in precooled (4°C) poly-
propylene collecting tubes. Five m1 of radial arterial blood was
collected into each tube and mixed. The tubes were immediately
put in crushed ice and transported to the laboratory. Tubes were
centrifuged at 4°C and 1500 x g for 10 minutes and the upper
portion of the plasma layer was removed and the centrifugation
and sampling repeated.
The remainder of the platelet-poor plasma was acidified with
1M hydrochloric acid (I volume of sample to 0,5 volume of acid)
and extracted into 10 volumes of diethyl-ether in polypropylene
tubes. The organic phase was separated, evaporated to dryness
under nitrogen (37°C) and the residue dissolved in assay buffer
(0,25 volumes); (3H) - PGF20! (Amersham International), which
does not crossreact appreciably with the antiserum used to deter-
mine TXB2 « 1%) and 6-ketoPGF 10! (2,2%), was used to monitor
1
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extraction recovery (50 Ill). This was greater than 85% in all cases.
The remainder of the specimen was stored in aliquots at -20°C
until assay of TXB2 and 6-ketoPGF,a.
Assay
For TXB2 and 6-ketoPGF,a determinations, in-house radio-
immunoassay kits were used. Antiserum and standard were
obtained from Seragen Inc. and titrated isotopes from New
England Nuclear Inc. The buffer used was O,OIM phosphate (pH
7,4) containing 1,0% bovine serum albumin, and separation of
bound from free tracer was achieved using I% I : I dextran-coated
charcoal in distilled water. Sample size was 100 III and results
were corrected using homologous nonspecific binding values (no
antiserum: 5 -7% of total counts) and an internal standard in-
corporated into the radio-immunoassay procedure. Intra-sample
coefficient of variation was less than 7%.
For {3-TG and C5a in EDTA plasma estimations commercial
radio-immunoassay kits were used.
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Fig. 1. C5a levels in the nifedipine and control groups expressed
as a percentage change from initial value (mean + 1 SEM)
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6-ketoPGF1a. Basal values ranging between 36 pg/ml and 467
pg/ml necessitated expressing the results as a percentage of the
initial values. There were no statistically significant differences at
any measurement times between treated and control patients or
between p-atiems who developed PD and those who remained
well.
Neutrophils. Patients who developed PD and unaffected ones
had similar neutrophil counts at measurement time 4. Nifedipine-
treated patients doubled their neutrophil counts half an hour after
insertion of the prosthesis (P < 0,05; unpaired Student's Hest) in
comparison with the control patients.
Fig. 2. C5a levels in patients who developed PO and those who
did not, expressed as a percentage change from initial values
(mean + 1 SEM).
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Incidence of PD. In the treatment group 1 patient developed
PD whereas 4 were affected in the control group. The incidence of
PD in the control group was 37% as opposed to 9% in the
treatment group.
Complement activi.ty. In awake patients basal values of C5a
ranged from °to 200 ng/m!. Because of the wide range, results
were expressed as a percentage of the basal value (measurement
time 1). Patients in the control group had a 5-fold increase in C5a
levels over the nifedipine group at measurement time 3 (major
trauma) (Fig. I) (P < 0,05; unpaired Student's r-test). The 5
patients who developed PD demonstrated an Il-fold increase in
C5a levels' at measurement time 3 compared with the 16 patients
who remained well (Fig. 2) (P < 0,001; unpaired Student's Hest).
At measurement times 4 and 5 the differences between the groups
were still statistically significant (P < 0,05; unpaired Student's
r-test).
TXB2 • The range of basal values was 6 - 135 pg/ml which
necessitated results being expressed as a percentage of those
values. The 5 patients who developed PD had a statistically
significant increase of TXB2 (P < 0,05; unpaired Student's Hest)
at measurement time 5 compared with the 16 patients who
remained well (Fig. 3). TXB2 levels in nifedipine-rreated and
control groups were not statistically different at any of the
measurement times (Fig. 4). This apparent contradiction arose
because of a very high TXB2 level at measurement time 5 in the 1
patient in the nifedipine group who developed PD. We have
demonstrated an excellent correlation (r = 0,89; P < 0,001) (Fig.
5) between {3-TG and TXB2 levels 24 hours after the hip replace-
ment operation in 9 randomly selected patients. This suggests
platelets as an important source of TXA2 synthesis.
Results
Criteria for diagnosing PD
All patients were examined twice daily for 1 week. The usual
panern in those affected was that the patient appeared well at one
postoperative visit, but at the next visit complained of shortness of
breath and 'feeling out of sons'. This usually occurred at the 24-
or 36-hour postoperative visits, at a stage at which post-anaesthetic
anoxia in surgery on extremities is not usually associated with
reduced Pa02 . 5
Examination of the affected patients revealed the following: (z)
tachypnoea (> 20/min); (iz) tachycardia (> llO/min); (iiz) Pa02
significantly lower than pre-operative level and expected for Fi02
- patients with a diagnosis of PD had blood gases measured twice
a day until they were at acceptable levels; and (iv) Pac02 values at
the lower limits of norma!.
A raised temperature was not a feature, clinical examination of
the lungs appeared normal while chest radiography, and fiow-
perfusion studies revealed no abnormalities. 4 These criteria
correspond with Gomez's type I ARDS c1assification. 3 The diag-
nosis of PD could not have been influenced by C5a and TXB2
results because they were only available 3 months later.
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Fig. 3. TXB2 levels in patients who developed PO and those who
did not, expressed as a percentage change from initial value
(mean + 1 SEM).
Fig. 4. TXB2 levels in nifedipine and control groups expressed as
a percentage change from initial values (mean + 1 SEM).
Fig. 5. Correlation coefficient between TXB2 and /3-TG levels 24
hours after total hip replacement.
These activated granulocyres lead to capillary endothelial
damage and allow plasma and red cell leakage into interstitial
tissues. Toxic oxygen radicals9 originating from the action of
5-lipoxygenase on arachidonic acid lO cause this endothelial
damage. Complement activation can thus lead to 'leaky lungs'.
In our control group it was demonstrated that total hip
replacement (probably the trauma of operation) activates the
complement system.
However, complement activation alone cannot explain the
marked rise in pulmonary vascular resistance which is an
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MODocytes. Patients in the control group who developed PD
had a reduced monocyte count to just outside the 0,05 significance
level in comparison with those who remained well about 30
minutes after major trauma (Mann-Whimey U-test).
Discussion
Many trigger mechanisms can activate the complement system,
the most common being trauma, severe sepsis and acute
pancreatitis, and inappropriate activation of this system may
harm the host. Hammerschmidt er al. 6 have demonstrated that
depending on the magnitude of the stimulus C5a activation is
a factor in the genesis of PD or ARDS. Craddock er al. 7 have
shown that changes in granulocyte counts are present in PD.
In simulated haemodialysis experiments in sheep and rabbits,
neutropenia and monocytopenia developed as a result of
complement activation within 30 minutes of exposure to cello-
phane. This was associated with PD lasting 3 - 4 hours. In our
patients who developed PD we could not demonstrate neutro-
penia but monocytopenia was present. When Craddock er
al. 'S7 animals were sacrificed at 30 minutes the animal's
pulmonary microvasculature was found to be occluded by
white blood cells. These observations suggested that a plasma
factor (probably the complement system) had promoted trans-
location of leucocyres from peripheral blood to form aggregates
occluding the pulmonary microvasculature. Evidence has been
provided that activated C5 or its desarginine derivative cause
granulocytes to become nonspecifically adhesive and that they
thus adhere to endothelium (hypermargination) and to each
other (aggreljation), and therefore could occlude the micro-
vasculature. I ,
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integral part of ARDS. It appears that this response is not due
to leucocyte aggregation but is probably mediated by substances
released by activated leucocytes2 Borg er al2 and Cooper er
al. II showed that this vascular reaction was prevented by
indomethacin administration, suggesting involvement of TXA2
synthesis. Because of the dose relationship between pulmonary
artery pressure rise and elevation of TXB2 levels it has been
demonstrated 11-13 that TXA2 synthesis is associated with the
pulmonary hypertension seen when plasma-eontaining zymosan-
activated complement is infused into animals. While Goldstein
et al. 14 found that zymosan stimulation of intact viable human
peripheral leucocytes led to generation of TXA2, McDonald er
al. l3 showed that zymosan-activated complement did not
stimulate leucocyte TXA2 synthesis in whole blood in vilro.
There is controversy over the source of TXA2 in the lungs.
Svensson el al. 15 showed that guinea-pig lung synthesises
TXA2 actively, and in isolated guinea-pig lungs Piper and
Samhoun 16 demonstrated that leukotrienes can induce TXA2
synthesis. McDonald er al. 13 also found that sheep lung and
pulmonary artery are active in TXA2 synthesis while
Ingerman-Wojenski et al. 17 have shown TXA2 and PGI2
synthesis by pulmonary endothelial cells. Although there is
controversy over its exact origin, the evidence presented
suggests that TXA2 is synthesised in the lung.
TXA? is undoubtedly synthesised by platelets l5 yet some
authors D,18 state that platelets take no part in TXA2 synthesis
in the lung. We, however, feel that there is evidence implicating
platelets in TXA2 synthesis in the lung. In hip replacement
operations, collagen, which is a potent stimulus of platelet
aggregation, is exposed. The pulmonary circulation acts as a
sieve and aggregated platelets translocate there. /3-TG is a
protein probably unique to platelets and is detected in plasma
only if there has been platelet aggregation and release of
TXA2 .19 In the present study we demonstrated an excellent
correlation between /3-TG and TXB2 levels 24 hours after
operation in 9 randomly selected patients. Therefore, whether
platelets are important in TXA2 synthesis in the lung remains
uncertain, but there is further proof that platelets synthesise
TXA2 •
In summary, activation of complement appears to be crucial
in the genesis of PD. Depending on the trigger mechanism,
additional factors become important in subsidiary roles as in
our patients, in whom trauma and collagen exposure were
presumed to be responsible for major platelet aggregation and
TXA2 synthesis.
PGI2- TXA2 ratio. In the human body a delicate balance
exists between TXA2 and PG12, preventing intravascular
thrombosis. According to our results the normal ratio between
TXA2 and PG12 is 1 : 2, but the stimulation of TXA2 synthesis
by major trauma changes the ratio to 20: 2. Other authors ll ,13
report similar results in vivo. The PGI2 fraction only changed
minimally.
Nifedipine-treated patients
In the 11 patients treated with nifedipine, C5a levels remained
normal at all the measurement times. In the 10 control patients
the C5a levels at measurement time 3 (major trauma) rose
significantly higher than in the nifedipine-treated patients
(P < 0,05; unpaired Student's Hest) (Fig. 1). Of the 11
patients treated with nifedipine, only 1 developed PD, but at
measurement time 3 this patient had a C5a level only 0,7 times
higher than the control value. It would thus appear that other
mechanisms, among which is collagen, may also trigger massive
platelet aggregation and TXA2 synthesis. This patient had the
highest TXB2 level of all 24 hours after the operation.
There is controversy over the effect of nifedipine on TXA2
and PGI2 synthesis. In isolated rat aorta Srivastava and
Awasthi20 demonstrated that. nifedipine significantly increased
the formation of PG12 in lung tissue but there was no effect on
TXA2 synthesis, while Han er al. 21 stated that TXA2 synthesis
by human platelets was reduced. Unlike Srivastava and
Awasthi20 we found no increased synthesis of PGI2 in our
nifedipine-treated patients.
Prevention by nifedipine of development of PD in hip
replacement operations is presumably due to its ability to
inhibit complement and leucocyte activation, thus minimising
capillary endothelial damage and TXA2 synthesis. In our.
nifedipine-treated patients, the granulocytecount was double
the pre-operative count half an hour after insertion of the
prosthesis, a further indication that nifedipine prevents
complement-induced leuco-aggregation in the lungs.
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